Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk
- Author(s)
- MacInnis, RJ; Jenkins, MA; Milne, RL; John, EM; Daly, MB; Andrulis, IL; Colonna, SV; Phillips, KA; kConFab Investigators; Le Marchand, L; Newcomb, PA; Phipps, A; Schmit, S; Macrae, F; Buchanan, D; Gallinger, S; Pai, RK; Samadder, NJ; Giles, GG; Southey, MC; Hopper, JL; Terry, MB;
- Details
- Publication Year 2025-12-03,Volume 9,Issue #1,Page pkae121
- Journal Title
- JNCI Cancer Spectrum
- Publication Type
- Research article
- Abstract
- Menopausal hormone therapy (MHT) users are at increased breast cancer (BC) risk and decreased colorectal cancer (CRC) risk compared with never users, but these opposing associations might differ by familial risk of BC and CRC. We harmonized data from three cohorts and generated separate BC and CRC familial risk scores (FRS) based on cancer family history. We defined moderate/strong family history as FRS ≥ 0.4, where 0.4 was equivalent to a 50-year-old woman with one parent diagnosed with either cancer at age 55 years. Of 24,486 women, 1,243 and 405 were diagnosed with incident BC and CRC, respectively. For BC, MHT hazard ratios (HRs) were 1.27 (95%CI = 1.11-1.45) for FRSBC<0.4, 1.01 (95%CI = 0.82-1.25) for FRSBC≥0.4 (P-difference = 0.08). For CRC, MHT HRs were 0.63 (95%CI = 0.50-0.78) for FRSCRC<0.4, 1.21 (95%CI = 0.73-2.00) for FRSCRC≥0.4 (P-difference = 0.03). Associations with MHT that apply to the general population might not hold for women at moderate/strong familial risk of these cancers.
- Publisher
- Oxford University Press
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1093/jncics/pkae121
- Open Access at Publisher's Site
https://doi.org/10.1093/jncics/pkae121- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-01-07 06:16:11
Last Modified: 2025-01-07 06:21:14